F 3796

Drug Profile

F 3796

Latest Information Update: 12 Dec 2006

Price : $50

At a glance

  • Originator Pierre Fabre
  • Class Neuroprotectants; Nootropics
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 29 Jun 2001 No-Development-Reported for Alzheimer's disease in France (Unknown route)
  • 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance
  • 09 Feb 1995 Preclinical development for Alzheimer's disease in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top